13F Filings History of Omega Fund Management, LLC

Latest 13F report
Q4 2025 - 17 Feb 2026
Value $
$286,520,063
Signature - Title
Eric Cooper - Chief Financial Officer, Omega Fund Management, LLC
Location
Boston, MA
Summary
This page shows a list of all the recent 13F filings made by Omega Fund Management, LLC. Form 13F is required to be filed within 45 days of the end of a calendar quarter. Omega Fund Management, LLC reported 11 stock holdings with total value $286,520,063 as of Q4 2025. Top holdings included NUVB, BBOT, BBNX, BCAX, and KMTS.

Notify me when Omega Fund Management, LLC files a new 13F portfolio report.

⭐ Subscribe ⭐
Holdings Value
Quarter Holdings Value $ Bought Sold Net Top Holdings Form Type Filing Time
Q4 2025 11 $286,520,063 +$3,160,500 -$33,221,500 -$30,061,000 NUVB, BBOT, BBNX, BCAX, KMTS 13F-HR 17 Feb 2026, 09:00
Q3 2025 12 $222,365,157 +$41,805,466 -$38,750,539 +$3,054,927 KMTS, BBNX, BBOT, BCAX, NUVB 13F-HR 14 Nov 2025, 09:00
Q2 2025 13 $154,437,217 $0 -$6,444,743 -$6,444,743 BBNX, KMTS, UPB, NUVB, BCAX 13F-HR 14 Aug 2025, 08:28
Q1 2025 13 $169,462,464 +$69,090,287 -$57,792 +$69,032,495 KMTS, BCAX, BBNX, NUVB, REPL 13F-HR 15 May 2025, 08:18
Q4 2024 1 $33,476,657 $0 $0 $0 UPB New Holdings 15 May 2025, 08:16
Q4 2024 12 $154,184,254 +$33,476,657 -$17,251,309 +$16,225,348 BCAX, NUVB, UPB, REPL, LXEO 13F-HR 14 Feb 2025, 09:00
Q3 2024 11 $160,008,733 +$56,152,436 -$5,912,090 +$50,240,346 BCAX, NUVB, REPL, LXEO, ENGN 13F-HR 14 Nov 2024, 07:56
Q2 2024 11 $134,971,971 +$8,687,893 -$8,475,165 +$212,728 NUVB, LXEO, REPL, ENGN, ALMS 13F-HR 14 Aug 2024, 16:00
Q1 2024 11 $155,010,742 +$3,109,046 -$23,506,520 -$20,397,474 NUVB, LXEO, REPL, ENGN, SANA 13F-HR 14 May 2024, 16:01
Q4 2023 14 $123,436,831 +$39,799,861 -$1,759,865 +$38,039,996 LXEO, REPL, NUVB, ENGN, MORF 13F-HR 14 Feb 2024, 16:00
Q3 2023 12 $108,875,488 $0 -$21,478,826 -$21,478,826 REPL, NUVB, IKNA, MORF, KRON 13F-HR 14 Nov 2023, 09:00
Q2 2023 12 $178,485,676 $0 -$23,155,354 -$23,155,354 REPL, NUVB, ALPN, MORF, IKNA 13F-HR 14 Aug 2023, 09:01
Q1 2023 14 $153,322,996 $0 -$121,880,577 -$121,880,577 REPL, NUVB, MORF, ALPN, IKNA 13F-HR 15 May 2023, 16:00
Q4 2022 16 $296,715,662 $0 -$48,738,666 -$48,738,666 IMGO, REPL, NUVB, MORF, ALPN 13F-HR 13 Feb 2023, 16:50
Q3 2022 19 $273,064,000 +$1,618,000 -$49,669,030 -$48,051,030 REPL, IMGO, NUVB, CINC, GOSS 13F-HR 14 Nov 2022, 14:04
Q2 2022 21 $313,294,000 +$386,000 -$50,282,551 -$49,896,551 REPL, NUVB, IMGO, MORF, CINC 13F-HR 15 Aug 2022, 09:00
Q1 2022 22 $488,614,000 +$16,947,000 -$6,123,200 +$10,823,800 NUVB, REPL, IMGO, MORF, KRON 13F-HR 13 May 2022, 14:10
Q4 2021 22 $707,272,000 +$9,022,000 -$74,661,431 -$65,639,431 NUVB, REPL, IMGO, MORF, KRON 13F-HR 14 Feb 2022, 06:31
Q3 2021 26 $891,379,000 +$108,854,291 -$49,306,980 +$59,547,311 NUVB, REPL, KRON, MORF, IMGO 13F-HR 15 Nov 2021, 16:00
Q2 2021 2 $279,245,000 $0 $0 $0 NUVB, SANA New Holdings 15 Nov 2021, 16:47
Q2 2021 23 $883,596,000 +$3,882,258 -$31,972,373 -$28,090,115 NUVB, REPL, MORF, KRON, IKNA 13F-HR 16 Aug 2021, 07:53
Q1 2021 2 $323,059,000 $0 $0 $0 NUVB, SANA New Holdings 15 Nov 2021, 16:42
Q1 2021 24 $1,057,223,000 +$393,791,304 -$56,264,473 +$337,526,831 NUVB, REPL, MORF, KRON, IKNA 13F-HR 17 May 2021, 11:20
Q4 2020 19 $666,876,000 +$218,935,000 -$17,389,853 +$201,545,147 REPL, KRON, MORF, SPRB, AVIR 13F-HR 16 Feb 2021, 15:29
Q3 2020 16 $369,660,000 +$34,458,972 -$19,431,393 +$15,027,579 REPL, MORF, GOSS, IMUX, ARQT 13F-HR 16 Nov 2020, 08:17
Q2 2020 15 $365,744,000 +$1,446,671 -$39,193,487 -$37,746,816 REPL, MORF, GOSS, ARQT, IMUX 13F-HR 14 Aug 2020, 17:50
Q1 2020 16 $241,630,000 +$31,533,698 -$23,622,052 +$7,911,646 REPL, MORF, GOSS, ARQT, TBIO 13F-HR 14 May 2020, 09:53
Q4 2019 14 $314,167,000 +$3,146,686 -$6,779,831 -$3,633,145 GOSS, REPL, MORF, TBIO, IMUX 13F-HR 13 Feb 2020, 09:50
Q3 2019 14 $324,015,000 +$2,368,977 -$7,393,720 -$5,024,743 GOSS, REPL, MORF, TBIO, IMUX 13F-HR 13 Nov 2019, 09:15
Q2 2019 15 $392,079,000 +$92,894,000 -$9,884,736 +$83,009,264 GOSS, REPL, MORF, TBIO, IMUX 13F-HR 13 Aug 2019, 08:55
Q1 2019 13 $311,888,000 $0 $0 $0 GOSS, REPL, TBIO, PRTK, OBSVF New Holdings 17 May 2019, 19:26
Q1 2019 13 $311,888,000 +$150,681,220 -$15,952,000 +$134,729,220 GOSS, REPL, TBIO, PRTK, OBSVF 13F-HR 15 May 2019, 08:49
Q4 2018 14 $134,874,000 +$15 -$1,018,402 -$1,018,387 REPL, TBIO, KZR, PRTK, OBSVF 13F-HR 11 Feb 2019, 09:21
Q3 2018 14 $211,385,000 +$85,422,000 -$4,127,409 +$81,294,591 REPL, PRTK, TBIO, OBSVF, KZR 13F-HR 06 Nov 2018, 17:51
Q2 2018 13 $135,522,000 +$42,830,000 -$78,323,121 -$35,493,121 TBIO, PRTK, OBSVF, KZR, SNNAQ 13F-HR 02 Aug 2018, 11:47
Q1 2018 11 $17,612 $0 $0 $0 OBSVF, ESSA Pharma 13F-HR 04 May 2018, 10:03
Q4 2017 12 $138,312,000 +$9,760,000 -$25,648,070 -$15,888,070 PRTK, JUNO, SNNAQ, OBSVF, JNCE 13F-HR 05 Feb 2018, 10:57
Q3 2017 11 $176,759,000 +$18,894,043 -$36,673,010 -$17,778,967 PRTK, JUNO, FGEN, SNNAQ, JNCE 13F-HR 03 Nov 2017, 10:52
Q2 2017 11 $160,239,000 +$11,937,000 -$21,396,893 -$9,459,893 PRTK, JUNO, FGEN, Nabriva Therapeutics, JNCE 13F-HR 26 Jul 2017, 10:19
Q1 2017 11 $153,841,000 +$12,747,000 -$1,703,381 +$11,043,619 PRTK, JUNO, FGEN, EGLTQ, NBRV 13F-HR 09 May 2017, 10:12
Q4 2016 11 $123,236,000 +$5,149,000 -$2,545,210 +$2,603,790 PRTK, JUNO, EGLTQ, FGEN, NBRV 13F-HR 10 Feb 2017, 10:01
Q3 2016 11 $130,994,000 $0 -$1,872,251 -$1,872,251 JUNO, PRTK, EGLTQ, FGEN, NBRV 13F-HR 02 Nov 2016, 13:07
Q2 2016 11 $134,798,000 +$6,792,060 -$355,983 +$6,436,077 JUNO, PRTK, EGLTQ, FGEN, NBRV 13F-HR 03 Aug 2016, 12:21
Q1 2016 11 $144,173,000 +$5,596,642 -$59,248 +$5,537,394 JUNO, PRTK, EGLTQ, FGEN, NBRV 13F-HR 02 May 2016, 11:51
Q4 2015 10 $179,685,000 +$1,866,487 -$5,920,549 -$4,054,062 JUNO, PRTK, EGLTQ, FGEN, NBRV 13F-HR 10 Feb 2016, 14:16
Q3 2015 10 $177,613,000 +$23,577,000 $0 +$23,577,000 JUNO, PRTK, EGLTQ, FGEN, NBRV 13F-HR 04 Nov 2015, 16:17
Q2 2015 7 $0 $0 $0 $0 13F-HR 10 Aug 2015, 14:03
Q1 2015 7 $0 $0 $0 $0 13F-HR 11 May 2015, 06:15
Q4 2014 7 $0 $0 $0 $0 13F-HR 23 Mar 2015, 13:35